Concentration and Activity of Lapatinib in Vestibular Schwannomas

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Vestibular SchwannomaNF2Neurofibromatosis 2Acoustic NeuromaAuditory Tumor
Interventions
DRUG

lapatinib

1500 mg lapatinib by mouth per day for 10 days

Trial Locations (7)

10016

New York University Medical Center, New York

10065

Weil Cornell Medical College, New York Presbyterian Hospital, New York

21287

Johns Hopkins Hospital, Baltimore

43210

Ohio State University Medical Center, Columbus

63110

Washington University Medical Center, St Louis

90057

House Reserach Institute, Los Angeles

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

The Children's Tumor Foundation

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

New York University

OTHER

collaborator

Ohio State University

OTHER

collaborator

House Research Institute

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER